35 results about "AIM antigen" patented technology

The present invention is directed to novel artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity when used in peptide immunogens comprising B cell epitopes or peptide haptens, a target antigenic site of a target antigen for eliciting antibodies thereto. The artificial Th epitopes are covalently linked to the target antigenic site and optionally an immunostimulatory sequence to provide effective and safe peptide immunogens.

The present invention relates to method of amplifying a population of antigen-specific memory CD4+ T cells using artificial presenting cells expressing HLA class II molecules. In particular, the present invention relates to a method of amplifying a population of antigen-specific memory CD4+ T cells comprising the steps of i) providing a population of artificial antigen presenting cells consisting host cells that are genetically modified to stably express at least one MHC class II molecule along with at least one accessory molecule ii) loading the population of artificial antigen presenting cells of step i) with an amount of at least one antigen of interest and iii) coculturing the suitable population of a T cells with the population of artificial antigen presenting cells of step ii).

The invention discloses a method and a device for predicting binding affinity based on antigen and antibody sequences. The method comprises the following steps: acquiring a first amino acid sequence of a target antigen and a second amino acid sequence of a target antibody, determining initial features of M dimensions according to the first amino acid sequence of the target antigen and the second amino acid sequence of the target antibody, and inputting the initial features of the M dimensions into a target feature fusion model to obtain M fusion features, and inputting the M fusion features into the target prediction neural network model to obtain predicted binding affinity parameters. The method can be at least applied to the field of intelligent medical treatment, and solves the technical problems of complex prediction mode and low prediction efficiency of the binding affinity of the antigen and the antibody in the prior art.

The invention relates to the technical field of immunity, in particular to a cBIN1 antibody and application thereof. Three CDR regions of a heavy chain of the cBIN1 antibody provided by the invention respectively have amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and three CDR regions of a light chain respectively have amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The antibody has good binding capacity with an antigen, and accurate detection of a target antigen can be realized by using the antibody to prepare a reagent.

One aspect of the present disclosure relates to an immunochromatographic detection method for a target antigen in a biological sample, comprising the step of joining a linker having a first antibody and a quantum dot bead having a second antibody, with respect to the target antigen. By using the quantum dot beads and the linker, the method can successfully amplify detection strength and significantly increase detection sensitivity through a simple process without causing a loss of antigens participating in detection when using only quantum dot beads. Furthermore, the present disclosure can significantly amplify detection strength without an additional washing step, thus enabling excellent detection and identification of a physiological substance in a biological sample, even in an actual product, and can be used to provide a product with a competitive price.

The invention discloses a method for obtaining antigen-specific T cells, which comprises the following steps: step 1, collecting peripheral blood, and separating to obtain mononuclear cells PBMC; step 2, obtaining immature DC cells; step 3, stimulating and inducing immature DC cells to be mature; 4, separating and purifying the initial T cells; 5, mixing the mature DC cells and the initial T cells according to the cell quantity ratio of 1: (5-120), adding a target antigen for co-stimulation culture for 1-3 rounds, and continuing to culture for 5-128 hours to obtain a cell suspension; 6, separating and purifying antigen-specific T cells; by adopting the method, the proportion of the antigen T cells in the co-culture cell suspension can be effectively increased.

A binary vector and the provision of expression of a target antigen-dependent regulatory cytokine using the synNotch technology, so as to partially release the cytokine to enhance the function of T cell and reduce the non-specific toxic and side effect of the cytokine. A synthetic notch receptor is used to construct plasmid vectors to achieve local cytokine secretion. One plasmid vector uses a specific antibody as an extracellular domain for identifying a target antigen, a notch core comprises a transmembrane domain and a specific enzyme cutting site on a notch receptor, and transcription factor GAL4VP64 is used as an intracellular domain. When the target antigen is identified, the enzyme cutting site on the notch will be identified by a corresponding enzyme to hydrolyze and cut the intercellular transcription factor GAL4VP64. Another plasmid vector carries DNA identification/binding domain GAL4UAS of transcription factor GAL4 and correspondingly activates a minimal promoter of a target gene, and after being hydrolyzed and cut, GAL4VP64 will be bound to the binding domain to activate transcription of subsequent genes so as to express IL12 and secrete same out of the cell.

The invention relates to the technical field of immunization and particularly relates to an antibody cBIN1 and application thereof. Three CDR regions of a heavy chain of the antibody cBIN1 provided bythe invention separately have amino acid sequences represented by SEQ ID NO: 1, 2 and 3; and three CDR regions of a light chain of the antibody cBIN1 separately have amino acid sequences representedby SEQ ID NO: 4, 5 and 6. The antibody has good binding ability with an antigen, and reagents prepared from the antibody can achieve accurate detection on target antigens.

In one aspect, the present disclosure relates to a quantum dot bead comprising a multifunctional ligand having a first conjugated material and a second antibody, and an immunochromatographic detectionmethod for a target antigen in a biological sample, comprising forming multiple bonds with a quantum dot having a second conjugated material. In addition, the present disclosure has the effect of remarkably amplifying the detection intensity and significantly improving the detection sensitivity without a separate washing step, and thus enables the detection and diagnosis of physiological substances in a biological sample even in an actual product, and may be used to provide a product with excellent price competitiveness.

The invention provides a data processing method and related equipment, and the method comprises the steps: querying data stored in a database according to the input data of a client, determining an abnormal problem of the client, carrying out the corresponding operation according to the antibody information stored in the database, and avoiding the continuous impact on the client from the same abnormal data. The method comprises the following steps: monitoring target input data corresponding to a target client; when the target antigen data matched with the target input data is stored in the database, obtaining target antibody information corresponding to the target antigen data, wherein multiple pieces of antigen data including target antigen data and multiple pieces of antibody informationincluding target antibody information are stored in the database, the target antigen data are input data causing abnormality of the target client, and the target antibody information comprises a source, a protocol number, data content and strategy configuration of the target input data; and executing a corresponding operation based on the strategy configuration of the target antibody information.

The invention discloses a label-free ratio fluorescence type antigen detection method. The method comprises the following steps: designing a single-stranded DNA which comprises a recognition DNA sequence for CRISPR and an aptamer of a target antigen, and constructing a component A by spacing the recognition DNA sequence and the aptamer through a plurality of continuous T basic groups; by taking a target antigen as a target, modifying an antibody of the target antigen on a 96-well plate to construct a component B; connecting the surface-carboxylated silicon dioxide microspheres with a DNA chain of which the tail end is modified with amino groups, and complementarily pairing auxiliary DNA with DNA with amino groups to form double chains, so as to construct a component C; adding the component A, the component B, the component C, copper ions, ascorbic acid, DAPI dye and exonuclease III into an object to be detected; and detecting red fluorescence and blue fluorescence of an object to be detected, and detecting the target antigen by a ratio fluorescence method. According to the ratio fluorescence method, the intensities of two kinds of fluorescence are compared to serve as signal parameters, the accuracy is higher, the sensitivity is higher, and the selectivity is better; and moreover, the sensitivity is improved, the defect that a traditional method needs to label an antibody is overcome, and the detection cost is saved.

The invention provides a bispecific antibody and application thereof in cancer treatment, the bispecific antibody comprises a first antigen binding domain specifically bound with a first antigen and a second antigen binding domain specifically bound with a second antigen, the first antigen is CD20, the second antigen is CD3, the first antigen binding domain targeting CD20 can be bound with a target antigen in a high affinity manner, and the second antigen binding domain targeting CD20 can be bound with the target antigen in a high affinity manner. A CD3-targeting second antigen binding domain selects a single-domain antibody structure with medium affinity, so that T cell immune response can be effectively mediated, and the situation that bispecific antibodies are gathered in T cell-enriched tissues such as spleen and lymph nodes in vivo to affect the anti-tumor effect can be prevented; a traditional antibody structural domain with a light chain and heavy chain structure is selected and combined with a single-domain antibody structural domain, so that the in-vivo half-life period of the bispecific antibody can be prolonged, and the anti-tumor activity is improved; in addition, the bispecific antibody provided by the invention can also reduce excessive immune factor secretion in the treatment process, and is helpful for reducing toxic and side effects.

The invention provides a cleaning-free universal ELISA fluorescence immunoassay probe as well as a preparation method and application thereof. The probe is characterized in that through an HBTU/DIEA coupling reaction, carboxyphenylboronic acid is modified onto g-C3N4, after ultrasonic exfoliation, a weak-fluorescence boric acid modified graphite phase carbon nitride nanosheet (BCNNS) can be obtained; an antibody (Ab) is labeled on the BCNNS to obtain a strong-fluorescence Ab-BCNNS composite material (ON), the fluorescence of the Ab-BCNNS composite material is quenched (OFF) along with additionof a target antigen, and the specific detection of the target antigen can be realized based on the ON-OFF phenomenon. And moreover, by changing the labeled antibody in the Ab-BCNNS, the selective detection of different target antigens can be realized.

The invention relates to the technical field of immunity, and particularly relates to a cBIN1 antibody and application thereof. Three CDR regions of a heavy chain of the cBIN1 antibody provided by the invention respectively have amino acid sequences shown as SEQ ID NO: 1, 2 and 3; and three CDR regions of a light chain respectively have amino acid sequences shown as SEQ ID NO: 4, 5 and 6. The antibody has good binding capability with an antigen; a reagent prepared from the antibody can realize the accurate detection on a target antigen.

The embodiment of the invention discloses a recombinant hansenula polymorpha cell disruption buffer solution for expressing a hand-foot-and-mouth disease vaccine antigen as well as a preparation method and application of the recombinant hansenula polymorpha cell disruption buffer solution. The cell disruption buffer solution is prepared from the following components: 1.00 g/L to 100.00 g/L of tromethamine, 10.00 g/L to 100.00 g/L of medicinal sodium chloride and 1.00 g/L to 100.00 g/L of glycerinum. By implementing the method disclosed by the invention, the breakage rate, the target protein content and the target antigen content of the recombinant hansenula polymorpha cell breakage product can be obviously improved.

The invention belongs to the technical field of biomedicine, and discloses a preparation method of an HA (hyaluronic acid) blocking agent and an antibody detection system. The preparation method comprises the following steps of purifying an antibody by ammonium sulfate with concentration of 33%-50%; adding glutaraldehyde into the obtained purified antibody, and crosslinking; after dialysis is completed, recycling the antibody, and storing; mixing a sample, a detection microsphere, a heterotropic antibody interference indication microsphere and a second antibody for marking a detectable signal,so as to form a reaction system; and detecting the detectable signal on the microsphere in a second antibody-antigen-first antibody-microsphere quaternary compound in the reaction system, comparing with a standard value or a standard curve, and determining whether a target antigen exists and/or the number of target antigens in the reaction system. The prepared HA blocking agent has the advantagesthat the anti-interference ability is strong, the HA interference is completely eliminated, the interference to immunity detection is avoided, the occurrence rate of false positive is effectively reduced, and the accuracy and precision rate of immunity detection are improved; the preparation method is simple, the control is easy, and the cost is low.

The invention discloses a kit for quantitatively detecting the content of pregnancy-related protein A. The kit comprises a kit body, a sealing cover, a protective cover and a reagent, wherein a solidphase carrier hole, a sample hole, a detection antibody hole, a fluorescein hole, a washing hole and a reading hole are sequentially formed in the kit body; the kit contains all reagent components required for completing immunodetection; the end part of the solid phase carrier loaded in the kit is coated with a capture antibody, and the solid phase carrier is immersed into each hole in the kit sothat the combination of a target antigen in a detected sample and subsequent detection steps can be completed, and the manufacturing and maintenance costs are greatly reduced; the kit is high in detection result accuracy, good in linear relation and high in specificity, and reliable clinical reference value can be provided for early screening of Down's syndrome and early prediction of atherosclerotic plaque rupture.

The invention relates to a chimeric antigen receptor (CAR) and application thereof. The invention provides an ROR1 specific chimeric antigen receptor which comprises a signal peptide, an anti-human ROR1scFv, a hinge region, a transmembrane region, a 4-1BB intracellular domain and a CD3 zeta intracellular domain, the anti-human ROR1scFv can be combined with a target antigen in a high affinity mode, and off-target benefits are prevented; furthermore, an Fc fragment is introduced into the chimeric antigen receptor, so that the tumor killing effect can be improved, immune factor storm can be prevented, the safety and effectiveness of treatment can be improved, and a new scheme is provided for development of related medicines and tumor immunotherapy.

The invention relates to a pharmaceutical composition containing dendritic cell exosome and application thereof, the exosome serves as a drug delivery carrier and forms a compound with a targeted Her2 specific antibody, the antibody has a nano antibody structure, can be combined with a target antigen in a high-specificity mode and improve treatment targeting, and the antibody is simpler in structure and lower in cost. Preparation and purification of the compound are facilitated; the exosome is a DC cell exosome Dex, and after DC cells are induced by a tumor marker and an immune factor, the DC cells can be effectively activated to improve the active ingredients and the anti-tumor efficacy of the exosome; the Dex-antibody compound shows a synergistic effect in in-vivo and in-vitro experiments, and can simultaneously improve the treatment effectiveness and killing targeting, prolong the lifetime of experimental animals and regulate the expression level of immune proteins.